![]() |
市场调查报告书
商品编码
1306529
冠状动脉栓塞保护装置的全球市场:规模,占有率,COVID-19影响分析(2023年~2029年):MedCoreCoronary Embolic Protection Device Market Size, Share & COVID-19 Impact Analysis | Global | 2023-2029 | MedCore | |
※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。
2022年全球冠状动脉栓塞防护装置市场规模将达8000万美元。预计未来该市场将以 -1.4% 的复合年增长率下降,到 2029 年将达到 7300 万美元。
本报告提供全球冠状动脉栓塞保护装置市场相关调查,提供市场概要,以及各市场区隔,各地区趋势,竞争情形等资讯。
The global embolic protection device market is projected to experience a decline in market value over the forecast period. In 2022, the market was valued at $80 million, and by 2029, it is estimated to reach $73 million. This indicates a negative compound annual growth rate (CAGR) of -1.4%. The anticipated decrease in market value suggests potential challenges or factors impacting the demand and adoption of embolic protection devices during the forecast period.
Through our research on the global coronary embolic protection device market, iData Research has conducted a thorough analysis of procedure volumes related to angiography, angioplasty (or PCI), atherectomy, and catheterization. This meticulous examination allows us to enhance the accuracy of our market sizing and provide comprehensive procedure volume data spanning a 10-year range across 70 countries. By incorporating procedure volumes into our analysis, we aim to provide you with a comprehensive understanding of the market dynamics and trends related to coronary embolic protection devices.
The use of embolic protection devices (EPDs) in interventional cardiology procedures has been limited due to the associated cost burden. This has resulted in physicians shifting away from utilizing EPDs, which in turn affects unit sales. EPDs are not deemed essential devices in interventional cardiology and may not always be covered under national reimbursement schedules. Consequently, the adoption of these devices is not expected to see significant growth, leading to a modest decline in the market.
The global coronary embolic protection device market was dominated by three key players: Boston Scientific, Medtronic, and Abbott. These companies held significant market share and played a crucial role in shaping the industry.
In 2022, Boston Scientific emerged as the leading competitor in the global coronary embolic protection device market. Their product offerings, such as the FilterWire EZ™ and SENTINEL™ Cerebral Protection System, contributed to their market dominance.
Medtronic held the second position in the coronary EPD market in 2022, with their Mo.Ma™ Ultra proximal cerebral protection device.
Abbott, as the third-leading competitor, offered the RX Accunet® embolic protection systems specifically designed for carotid interventions, featuring rapid exchange delivery.
These three companies played a significant role in driving innovation and competition within the coronary embolic protection device market.
Throughout this research series, iData Research has covered over 70 countries across the globe in great detail. The regions covered include: